TP53 and cancer: Indeed, NF-κB inhibition to restore wt p53 function is a rational approach that has previously been demonstrated using derivatives of 9-aminoacridine in renal cell carcinomas [43], and small molecule curaxins in several cancer cell lines and mouse tumour xenografts [44].